M&A Fireworks: Shire Buys Jerini For €328 Million
This article was originally published in The Pink Sheet Daily
Executive Summary
Jerini secures a hefty payout, despite FDA deeming HAE candidate Firazyr “not approvable.”
You may also be interested in...
Persistence, Secondary Endpoints Helped Shire Get FDA Nod For Firazyr Novel PRO
FDA questioned the validity of icatibant’s patient-reported outcomes instrument during a first-cycle review and found it “difficult to interpret.” But conducting a third trial and running validity testing after FDA issued final PRO guidance, as well as key secondary endpoints that supported the treatment effect, helped sway regulators.
Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling
An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.
Shire Seeks Advantage For Firazyr In HAE Through Self-Administration Data In Labeling
An FDA advisory panel will meet June 23 to assess the drug, which would enter a crowded U.S. market for hereditary angioedema.